The Predictive Value of Cystatin C in Monitoring of B Non-Hodgkin Lymphomas: Relation to Biochemical and Clinical Parameters

Table 1

Comparison of cystatin C levels measured at the time of diagnosis and before IV cycle of chemotherapy in patients with partial or complete remission.

Group	No.	Median and range; (ng/mL)		Wilcoxon Z	P
		Time of diagnosis	Before IV chemotherapy
All patients^a	40	944,63; (562,47–1594,30)	890,07; (618,0–1415,20)	−2,245^∗	0,025
Aggressive	34	944,63; (562,47–1594,30)	887,46; (618,0–1415,20)	−2,248^∗	0,025
Extranodal	19	931,30; (562,47–1594,30)	995,76; (698,38–1415,20)	−1,087	0,277
Nodal	15	957,96; (599,45–1451,60)	823,36; (618,0–1182,90)	−1,874	0,061

∗Statistically significant difference.
^aTotal group of patients.